Peggi Ryan
Family · Pueblo, CONPI 1366419582
Payments from drug & device makers
Across 244 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$538
- Novo Nordisk$433
- Bayer$301
- Lilly USA, LLC$285
- Amgen$275
- plus $2K from 40 others
What the payments were for
- Food & beverage$5,65599%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,703 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $60,839 |
| MounjaroTirzepatide | 47 | $58,201 |
| FarxigaDapagliflozin Propanediol | 37 | $53,571 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $50,759 |
| XareltoRivaroxaban | 21 | $30,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $29,065 |
| RybelsusSemaglutide | 11 | $27,056 |
| EliquisApixaban | 18 | $24,988 |
| VraylarCariprazine Hcl | 13 | $19,097 |
| GemtesaVibegron | 20 | $18,694 |
| Spiriva HandihalerTiotropium Bromide | 14 | $12,916 |
| MyrbetriqMirabegron | 16 | $12,161 |
| Lidocaine | 39 | $6,537 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,659 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $4,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $285 | $119,04085 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,420 | $108,989107 claims |
| GSKTrelegy Ellipta | $59 | $29,06528 claims |
| Novo NordiskRybelsus | $433 | $27,05611 claims |
| PfizerEliquis | $192 | $24,98818 claims |
| AbbVieVraylar | $538 | $19,09713 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $18,69420 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $12,16116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Pueblo
- Lisa CloughPueblo$7K
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Courtney WeirFort Collins$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.